Agenus Inc., an immuno-oncology company, focuses on the discovery and development of revolutionary new treatments that engage the body’s immune system to benefit patients suffering from cancer. Antibody Discovery Platforms and Checkpoint Modulator (CPM) Programs In 2014, the company acquired its Retroviral B Lymphocyte Display, or Retrocyte Display, platform as a result of its acquisition of 4-Antibody AG, a private European-based biopharmaceutical company. Retrocyte Display is a proprietary antibody discovery platform designed for the rapid discovery and optimization of fully-human and humanized monoclonal antibodies against a range of molecular targets. The company’s Retrocyte Display platform uses a high-throughput approach incorporating human antibody libraries expressed in mammalian B-lymphocytes and is designed to screen and generate therapeutic antibody drug candidates. The company complemented this platform in April 2015 with the acquisition of its SECANT yeast display antibody discovery platform from Celexion, LLC, or Celexion, and in September 2015 with the license to a phage display library. The addition of the phage display library and SECANT yeast display platform in combination with the company’s Retrocyte Display platform gives the company integrated and highly productive antibody discovery platforms. The company has the potential to integrate three complementary antibody display technologies with computational, structured-based design approaches to discover and optimize monoclonal antibodies as future medicines. The company and its partners have pre-clinical and clinical programs exploring fully human and humanized monoclonal antibodies against various major checkpoint targets, including GITR, OX40, CTLA-4, PD-1, TIM-3, LAG-3, CEACAM1 and other undisclosed targets. The company is working to discover and develop monoclonal CPM antibodies to modulate the activity of these targets, selectively reactivate the immune system and thwart attempts by cancer to evade destruction. In 2015, the company filed investigational new drug applications (INDs) for antibodies targeting CTLA-4 and GITR (filed with Incyte Corporation). In January 2016, the company announced that the U.S. Federal Drug Administration gave clearance to begin clinical trials with these two CPM candidates. Clinical trials with these CPMs are planned to initiate in the first half of 2016. In addition, the company has product candidates targeting OX40 and PD-1 advancing into IND-enabling studies, and expects to initiate clinical trials for one or more of these compounds during the second half of 2016. Partnered CPM Programs In January 2015, the company entered into a global alliance with Incyte Corporation to discover, develop and commercialize novel immuno-therapeutics using its antibody platforms. The collaboration was initially focused on four CPM programs targeting GITR, OX40, TIM-3 and LAG-3, and in November 2015, the company expanded its alliance by adding three additional novel undisclosed CPM targets. In addition, in 2014, the company entered into a collaboration and license agreement with Merck Sharpe & Dohme to discover and optimize fully-human antibodies against two undisclosed CPM targets. Under the terms of the agreement, Merck Sharpe & Dohme is responsible for the clinical development and commercialization of antibodies generated under the collaboration. The company also continues to collaborate with Recepta SA on the development of antibodies targeting CTLA-4 and PD-1, and expects to continue exploring additional future collaborations. Vaccine Platform Programs The company’s vaccine platform programs for the treatment of cancer include its HSP based Prophage vaccine candidates, and the company’s synthetic vaccine candidates, AutoSynVax (ASV) and PhosphoSynVax (PSV). Prophage Vaccine Candidates The company’s Prophage cancer vaccine candidates are autologous therapies derived from patient cancer tissues that are surgically removed. The company’s Prophage vaccines are being studied in two different settings of glioblastoma multiforme, such as patients who have been newly diagnosed, as well as those with r
(AGEN:Consolidated Issue listed on NASDAQ Capital Market)
3 Forbes Road
Lexington, MA 02421
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for AGEN.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact AGENUS INC, please visit www.agenusbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.